Literature DB >> 21515949

Hemosiderin detected by T2*-weighted magnetic resonance imaging in patients with unruptured cerebral aneurysms: indication of previous bleeding?

Shihomi Takada1, Takashi Inoue, Kuniyasu Niizuma, Hiroaki Shimizu, Teiji Tominaga.   

Abstract

Previous bleeding from a cerebral aneurysm indicates a higher risk of rupture. Hemosiderin may be detected during aneurysm surgery or by preoperative imaging sensitive to hemosiderin. The detection of hemosiderin deposits by T(2)*-weighted magnetic resonance (MR) imaging was evaluated in 49 patients with unruptured cerebral aneurysms who underwent open surgery. MR imaging was performed using 3.0 tesla MR scanner. Two sequences of T(2)*-weighted imaging, and proton density images were obtained. Preliminary study in patients with old subarachnoid hemorrhage provided the definitions of likely pathological findings during surgery and on T(2)*-weighted imaging due to previous hemorrhage. Hemosiderin deposits in the subarachnoid space were observed during surgery in 9 of the 49 patients, although no obvious rupture site was detected around the aneurysm wall. Size, presence of bleb, location, and number of aneurysms showed no significant difference between patients with and without hemosiderin deposition. Hypointense areas on T(2)*-weighted imaging were recognized in four patients. The mean size of the aneurysms in these patients was 9.8 mm, significantly larger than those in other patients (p = 0.029). Hemosiderin deposits were observed during surgery in sites close to the lesions on T(2)*-weighted imaging in two of these four patients. Hemosiderin deposits are not rare in patients with unruptured aneurysms, and preoperative T(2)*-weighted imaging can detect such deposits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515949     DOI: 10.2176/nmc.51.275

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  7 in total

1.  Frequency and appearance of hemosiderin depositions after aneurysmal subarachnoid hemorrhage treated by endovascular therapy.

Authors:  Bernhard Falter; Martin Wiesmann; Jessica Freiherr; Omid Nikoubashman; Michael Mull
Journal:  Neuroradiology       Date:  2015-07-19       Impact factor: 2.804

2.  Prevalence of superficial siderosis following singular, acute aneurysmal subarachnoid hemorrhage.

Authors:  N Lummel; C Bernau; N Thon; K Bochmann; J Linn
Journal:  Neuroradiology       Date:  2014-12-23       Impact factor: 2.804

3.  Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer.

Authors:  Avigdor Leftin; Huiyong Zhao; Mesru Turkekul; Elisa de Stanchina; Katia Manova; Jason A Koutcher
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

4.  Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy.

Authors:  Avigdor Leftin; Nir Ben-Chetrit; Johanna A Joyce; Jason A Koutcher
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

5.  "Microbleeding" from intracranial aneurysms: Local hemosiderin deposition identified during microsurgical treatment of unruptured intracranial aneurysms.

Authors:  Eric S Nussbaum; Archie Defillo; Andrea Zelensky; Swaroopa Pulivarthi; Leslie Nussbaum
Journal:  Surg Neurol Int       Date:  2014-02-27

6.  Longitudinal profile of iron accumulation in good-grade subarachnoid hemorrhage.

Authors:  Christoph Scherfler; Alois Josef Schiefecker; Margarete Delazer; Ronny Beer; Thomas Bodner; Georg Spinka; Mario Kofler; Bettina Pfausler; Christian Kremser; Michael Schocke; Thomas Benke; Elke R Gizewski; Erich Schmutzhard; Raimund Helbok
Journal:  Ann Clin Transl Neurol       Date:  2016-09-01       Impact factor: 4.511

7.  Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer.

Authors:  Avigdor Leftin; Nir Ben-Chetrit; Florian Klemm; Johanna A Joyce; Jason A Koutcher
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.